NCT01482728View on ClinicalTrials.gov

Bristol-Myers Squibb Dasatinib Src Inhibition in Endometrial Cancer

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

January 31, 2012

Primary Completion Date

May 31, 2015

Study Completion Date

December 31, 2015

Conditions
Endometrial Cancer
Interventions
DRUG

Dasatinib

100 mg dasatinib, the day before surgery and the day of surgery

DRUG

Dasatinib

200 mg dasatinib the day before surgery and the day of surgery

Trial Locations (1)

22908

University of Virginia, Charlottesville

All Listed Sponsors
lead

University of Virginia

OTHER

NCT01482728 - Bristol-Myers Squibb Dasatinib Src Inhibition in Endometrial Cancer | Biotech Hunter | Biotech Hunter